2024
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease
Lizama B, Williams C, North H, Pandey K, Duong D, Di V, Mecca A, Blennow K, Zetterberg H, Levey A, Grundman M, van Dyck C, Caggiano A, Seyfried N, Hamby M. CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease. Alzheimer's & Dementia 2024, 20: 6860-6880. PMID: 39166791, PMCID: PMC11485314, DOI: 10.1002/alz.14152.Peer-Reviewed Original ResearchVolumetric magnetic resonance imagingMagnetic resonance imagingPharmacodynamic biomarkersMeta-analysisClinical developmentCerebrospinal fluidPhase 2 clinical trialResonance imagingAlzheimer's diseaseMechanism of actionClinical trialsTandem mass tag-mass spectrometryClinical cohortMild to moderate ADCandidate biomarkersCT1812CohortBiomarker signaturesBiomarkersProteomic findingsUnbiased analysisNetwork analysisAmyloid-betaSynaptic biologyBiological impactRelationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients
Matthews D, Kinney J, Ritter A, Andrews R, Strom E, Lukic A, Koenig L, Revta C, Fillit H, Zhong K, Tousi B, Leverenz J, Feldman H, Cummings J. Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2024, 10: e12490. PMID: 38988416, PMCID: PMC11233274, DOI: 10.1002/trc2.12490.Peer-Reviewed Original ResearchFluorodeoxyglucose positron emission tomographyGlial fibrillary acidic proteinPositron emission tomographyMagnetic resonance imagingPlasma biomarkersVolumetric magnetic resonance imagingMild to moderate ADFDG positron emission tomographyPhase 2 clinical trialNeurofilament light chainGlial fibrillary acidic protein concentrationFibrillary acidic proteinInflammation-related proteinsTemporal cortexLeft inferior temporal cortexModerate ADCognitive endpointsFluorodeoxyglucosePET uptakeInflammation biomarkersBaseline MMSEMild-to-moderate Alzheimer's disease patientsImaging biomarkersBiomarker heterogeneityEmission tomography
2003
MRI-Guided SPECT Perfusion Measures and Volumetric MRI in Prodromal Alzheimer Disease
El Fakhri G, Kijewski M, Johnson K, Syrkin G, Killiany R, Becker J, Zimmerman R, Albert M. MRI-Guided SPECT Perfusion Measures and Volumetric MRI in Prodromal Alzheimer Disease. JAMA Neurology 2003, 60: 1066-1072. PMID: 12925361, DOI: 10.1001/archneur.60.8.1066.Peer-Reviewed Original ResearchConceptsRostral anterior cingulateCaudal anterior cingulateMagnetic resonance imagingAnterior cingulateSuperior temporal sulcusPosterior cingulateBasal forebrainTemporal hornEntorhinal cortexTemporal sulcusGroup differencesMemory problemsNondemented patientsFollow-upQuantitative single-photon emissionProdromal phase of Alzheimer's diseaseReceiver operating characteristic curve analysisYears of follow-upAlzheimer's diseasePhase of Alzheimer's diseaseCharacteristic curve analysisVolumetric magnetic resonance imagingMagnetic Resonance Imaging AnalysisMagnetic resonance imaging measuresSPECT analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply